Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

143

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

143 results for “Patient Choice”

Learn how ShareScore rates datasets ↗
dryad36/100

Patient preferences for HIV service delivery models: A discrete choice experiment in Kisumu, Kenya

<p><strong>Background</strong>: Novel "differentiated service delivery" models for HIV treatment that reduce clinic visit frequency, minimize waiting time, and deliver treatment in the community promise retention improvement for HIV treatment in Sub-Saharan Africa.  Quantitative assessments of differentiated service delivery (DSD) feature most preferred by patient populations do not widely exist but could inform the selection and prioritization of different types of DSD models.</p> <p><strong>Methods</strong>: We used a discrete choice experiment (DCE) to elicit patient preferences for HIV treatment services and how they differ across DSD models. We surveyed adults aged &gt;18 years, enrolled in HIV care for &gt;6 months between February and March 2019 at four facilities in Kisumu County, Kenya.  DCE offered patients a series of comparisons between three treatment models, each of which varied in seven attributes: ART refill location, the quantity of ART dispensed at each refill, medication pick-up hours, type of adherence support, clinical visit frequency, staff attitude, and professional cadre of the person providing ART refills.  We used a hierarchical Bayesian model to estimate attribute importance and the relative desirability of care characteristics, latent class analysis (LCA) for groups of preferences, and mixed logit model for willingness to trade analysis.</p> <p><strong>Results</strong>: Of 242 patients, 128 (53.8%) were females and 150 (62.8%) lived in rural areas.  Patients placed the greatest importance on ART refill location [19.5% (95%CI 18.4, 20.6)] and adherence support [19.5% (95%CI 18.7, 20.3)], followed by staff attitude [16.1% (95%CI 15.1, 17.2)]. In the mixed logit, patients preferred the nice attitude of the staff (coefficient=1.60), refill ART health center (Coeff=1.58), and individual adherence support (Coeff=1.54), 3 or 6 months for ART refill (Coeff=0.95 &amp; 0.80, respectively) and pharmacists (instead of lay health workers) providing ART refill (Coeff=0.64). No differences were observed by gender or urbanicity. LCA revealed two distinct groups (59.5% vs.40.5%).</p> <p><strong>Conclusions</strong>: Participants preferred 3 to 6-month refill intervals or clinic visit spacing, which DSD provides for stable patients. While DSD has also encouraged community ART group options, our results suggest strong patient preferences for ART refills from health centers or by pharmacists over lay caregivers or community members. These preferences held across gender and urban/rural subpopulations. </p>

opencc-zeroOct 2022View details →
ClinicalTrials.gov36/100

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

ClinicalTrials.gov study NCT02000622. IPD Sharing: YES. Countries: 19. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

ClinicalTrials.gov study NCT01564784. IPD Sharing: YES. Countries: 20. Publications: 13.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemi

ClinicalTrials.gov study NCT04778397. IPD Sharing: NO. Countries: 15. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitin

ClinicalTrials.gov study NCT01085136. IPD Sharing: Not stated. Countries: 23. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

ClinicalTrials.gov study NCT01318408. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

ClinicalTrials.gov study NCT01849874. IPD Sharing: YES. Countries: 19. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

ClinicalTrials.gov study NCT01482962. IPD Sharing: Not stated. Countries: 31. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics

ClinicalTrials.gov study NCT00742573. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

ClinicalTrials.gov study NCT01926782. IPD Sharing: Not stated. Countries: 8. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus

ClinicalTrials.gov study NCT02319525. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

ClinicalTrials.gov study NCT03703375. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

ClinicalTrials.gov study NCT04379271. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With a

ClinicalTrials.gov study NCT02915744. IPD Sharing: Not stated. Countries: 10. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

ClinicalTrials.gov study NCT00635492. IPD Sharing: Not stated. Countries: 5. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

ClinicalTrials.gov study NCT00875667. IPD Sharing: Not stated. Countries: 14. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

ClinicalTrials.gov study NCT00388726. IPD Sharing: Not stated. Countries: 17. Publications: 7.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Empowering Patients On Choices for Renal Replacement Therapy (Aim 3) (EPOCH-RRT)

ClinicalTrials.gov study NCT02488317. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

ClinicalTrials.gov study NCT02023879. IPD Sharing: Not stated. Countries: 8. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surge

ClinicalTrials.gov study NCT02506153. IPD Sharing: Not stated. Countries: 3. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.